Otsuki Saburo
Zikei Institute of Psychiatry.
Seishin Shinkeigaku Zasshi. 2004;106(9):1124-9.
The history of academic meetings, research institutes, and governmental or private grants, as well as physiological, biochemical, pharmacological, histostructural, brain imaging, animal model, and molecular genetic studies related to biological psychiatry in Japan were reviewed. We expect to be able to elucidate individually different factors related to an attack of illness or relapse. In the treatment of functional mental disorders, future development depends on new drug creations that do not have any side effects or drug-dependence characteristics. Special attention should be paid to new anti-depressants or anti-anxiety drugs that have prompt euphoric effects. Instruments attached to a patient should be as small as possible to avoid psychological stress, and a telemetry feature is desirable to enable recording even during an acute severe stage of behavior disorder. To avoid fixation to the present treatment manual based on EBM (evidence-based medicine), new hypotheses should be investigated. I suggest my own plan in this speech.
回顾了日本学术会议、研究机构以及政府或私人资助的历史,以及与生物精神病学相关的生理、生化、药理、组织结构、脑成像、动物模型和分子遗传学研究。我们期望能够阐明与疾病发作或复发相关的个体差异因素。在功能性精神障碍的治疗中,未来的发展取决于没有任何副作用或药物依赖特征的新药研发。应特别关注具有快速欣快作用的新型抗抑郁药或抗焦虑药。附着在患者身上的仪器应尽可能小,以避免心理压力,并且具有遥测功能以便即使在行为障碍的急性严重阶段也能进行记录。为避免拘泥于基于循证医学的现行治疗手册,应研究新的假说。我在本次演讲中提出了自己的计划。